CAG
AXSM icon

Csenge Advisory Group’s Axsome Therapeutics AXSM Stock Holding History

Csenge Advisory Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$474K Sell
2,807
-1,189
-30% -$205K 0.02% 444
2025
Q4 		$730K Buy
+3,996
New +$558K 0.03% 361

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Csenge Advisory Group's AXSM Position: Q1 2026 in Review

Csenge Advisory Group reduced its Axsome Therapeutics (AXSM) stake by 30% in Q1 2026, selling an estimated $205K and leaving 2,807 shares worth $474K. The position accounts for 0.02% of the portfolio, ranked #444.

Csenge Advisory Group first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $730K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Csenge Advisory Group held 2,807 shares of Axsome Therapeutics worth $474K as of Q1 2026.
  • Csenge Advisory Group sold 1,189 Axsome Therapeutics shares in Q1 2026, an estimated $205K.
  • Axsome Therapeutics made up 0.02% of Csenge Advisory Group's portfolio in Q1 2026, its #444 holding.
  • Csenge Advisory Group first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Csenge Advisory Group's Axsome Therapeutics position peaked at $730K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Csenge Advisory Group's 13F filing for Q1 2026, filed 30 Apr 2026.